AC
CRSP icon

Allstate Corporation’s CRISPR Therapeutics CRSP Stock Holding History

Allstate Corporation’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$436K Buy
+7,994
New +$421K ﹤0.01% 1086
2020
Q4 		– Sell
-2,690
Closed -$225K – 707
2020
Q3 		$225K Sell
2,690
-806
-23% -$71.5K 0.01% 628
2020
Q2 		$257K Buy
+3,496
New +$204K 0.01% 616

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Allstate Corporation's CRSP Position: Q2 2026 in Review

Allstate Corporation opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 7,994 shares worth $436K. The stake represents ﹤0.01% of the portfolio and ranks #1086 among its holdings. This is a return to the name: Allstate Corporation previously reported a position in CRSP as recently as Q3 2020.

Allstate Corporation first reported a position in CRSP in Q2 2020 and has held it in 3 quarters since. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Allstate Corporation held 7,994 shares of CRISPR Therapeutics worth $436K as of Q2 2026.
  • CRISPR Therapeutics was a new Allstate Corporation position in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Allstate Corporation's portfolio in Q2 2026, its #1086 holding.
  • Allstate Corporation first reported a position in CRISPR Therapeutics in Q2 2020 and has held it in 3 quarters since.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Allstate Corporation's 13F filing for Q2 2026, filed 13 Aug 2026.